# 2025-23705: HHS Proposes GUARD Model to Curb Medicare Drug Cost Increases

2025-23705, Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model, is a Federal Register proposed rule from Health and Human Services Department, Centers for Medicare & Medicaid Services published 2025-12-23, effective 2027-01-01 (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2025-23705
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-23705
- Title: Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model
- Type: Proposed Rule
- Agencies: Health and Human Services Department; Centers for Medicare & Medicaid Services
- Citation: 90 FR 60338
- Published: 2025-12-23
- Effective: 2027-01-01
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: 0938-AV74
- Last updated: 2026-06-11

## In one line

HHS Proposes GUARD Model to Curb Medicare Drug Cost Increases

## Summary

The GUARD Model aims to help Medicare save money by changing how drug price increases are handled for certain medicines in Part D. This new plan could lower costs while keeping or improving care for people on Medicare. Comments on this idea are open until February 23, 2026, so now’s the time to weigh in!

## Abstract

This proposed rule would implement the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model to test a new Medicare payment model under section 1115A of the Social Security Act. The model proposes a test of an alternative payment method for calculating inflation rebates for certain Part D drugs and biological products. The proposed GUARD Model would test whether changing the calculation of the Part D inflation rebate would reduce costs for the Medicare program while preserving or enhancing quality of care for Part D enrollees.

## Effects PRIA read

- New Part D Rebate Test for Medicare: benefit, medium. CMS proposes the GUARD Model to test a new way to calculate Part D inflation rebates for certain drugs starting January 1, 2027. The test aims to see whether this alternative rebate method would reduce Medicare and taxpayer spending while preserving or enhancing quality of care for people on Medica…
- Which Drugs Are In or Out: mixed, medium. The GUARD Model would include sole‑source Part D drugs and sole‑source biological products in specific therapeutic categories (for example, Analgesics; Anticonvulsants; Antidepressants; Antineoplastics; Antipsychotics; Antivirals; Cardiovascular Agents; Blood Glucose Regulators; Respiratory Tract/P…
- Manufacturers May Owe International‑Benchmark Rebates: benefit, medium. Under GUARD, CMS would set an applicable international benchmark price for each included drug using selected reference countries and would compare that benchmark to the Medicare net price (WAC minus rebates and discounts). If the Medicare net price is greater than the applicable international bench…
- International Price Benchmarking Method: mixed, low. CMS would use a set of reference countries (Australia; Austria; Belgium; Canada; Czech Republic; Denmark; France; Germany; Ireland; Israel; Italy; Japan; the Netherlands; Norway; South Korea; Spain; Sweden; Switzerland; and the United Kingdom) and two methods to set an international benchmark: Meth…
- CMS Will Track Effects on Benefits and Cost Sharing: benefit, low. CMS will evaluate the GUARD Model by examining Medicare net spending and additional outcomes, including whether Part D plan benefits change for GUARD drugs and whether beneficiary cost sharing for those drugs is affected. The evaluation is part of the test to see if program expenditures fall while…

## Related documents

- [2026-22812](https://policyrisk.com/federal-register/2026-22812): Medicare and Medicaid Programs; Cutting Administrative Requirements for Excellence in Patient Care, 2026-11-10
- [2026-22750](https://policyrisk.com/federal-register/2026-22750): Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the E…, 2026-11-09
- [2026-22792](https://policyrisk.com/federal-register/2026-22792): Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program, 2026-11-09
- [2026-22743](https://policyrisk.com/federal-register/2026-22743): Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage…, 2026-11-09
- [2026-22739](https://policyrisk.com/federal-register/2026-22739): Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; i…, 2026-11-06
- [2026-22381](https://policyrisk.com/federal-register/2026-22381): Medicare and Medicaid Programs; Organ Procurement Organizations Conditions for Coverage: Revisions to the Conditions for Coverage, 2026-11-03

## Sources
- [2025-23705 on federalregister.gov](https://www.federalregister.gov/documents/2025/12/23/2025-23705/guarding-us-medicare-against-rising-drug-costs-guard-model)
- [2025-23705 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-12-23/pdf/2025-23705.pdf)

## Related
- [Previous: 2025-23704, Debt Collection Authorities Under the Debt Collection Improvement Act of 1996](https://policyrisk.com/federal-register/2025-23704)
- [Next: 2025-23719, Airworthiness Directives; Honda Aircraft Company LLC Airplanes](https://policyrisk.com/federal-register/2025-23719)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-23705 (as of 2026-06-11).
